Several inhibitors of this pathway, such as rapamycin and its derivatives which inhibit mTOR (FRAP1) and the PI3K (PIK3C2A) inhibitor wortmannin, are in fact now being actively evaluated in clinical trials for other cancers [31,34]. This evidence concerns the gene PIK3CA and cancer.